MCP-1 in urine as biomarker of disease activity in Systemic Lupus Erythematosus

Cytokine

Volumn 60, Issue 2, 2012, Pages 583-586

  Barbado, Julia ^a   Martin, Debora ^a   Vega, Luisa ^a   Almansa, Raquel ^a   Gonçalves, Lisbeth ^a   Nocito, Mercedes ^a   Jimeno, Antonio ^a   Ortiz de Lejarazu, Raúl ^a   Bermejo Martin, Jesus F ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Activity; MCP 1; SLE; Urine

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

EID: 84866768374     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.07.009     Document Type: Article

References (21)

1. Systemic lupus erythematosus - an update. Drug Ther Bull 2011;49:81-4.
2. Jakes R.W., Bae S.C., Louthrenoo W., Mok C.C., Navarra S.V., Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012, 64:159-168.
3. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318.
4. Slawsky K.A., Fernandes A.W., Fusfeld L., Manzi S., Goss T.F. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken) 2011, 63:1224-1232.
5. Lau C.S., Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009, 5:400-404.
6. Ahearn J.M., Liu C.C., Kao A.H., Manzi S. Biomarkers for systemic lupus erythematosus. Trans Res 2012, 159:326-342.
7. Yu S.L., Kuan W.P., Wong C.K., Li E.K., Tam L.S. Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol 2012, 715190.
8. Mok C.C. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010, 638413.
9. Willis R., Seif A., McGwin G., Martinez-Martinez L.A., Gonzalez E.B., Dong N., et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV). A multiethnic US Cohort. Lupus 2012, 21:830-835.
10. Vega L., Barbado J., Almansa R., Gonzalez-Gallego R., Rico L., Jimeno A., et al. Prolonged standard treatment for systemic lupus erythematosus fails to normalize the secretion of innate immunity-related chemokines. Eur Cytokine Netw 2010, 21:71-76.
11. Hermansen ML, Hummelshoj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, et al. Increased serum beta2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus. Lupus 2012.
12. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
13. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
14. Li Q.Z., Xie C., Wu T., Mackay M., Aranow C., Putterman C., et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005, 115:3428-3439.
15. Alzawawy A., Zohary M., Ablordiny M., Eldalie M. Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis. Int J Rheum Dis 2009, 12:311-318.
16. Esche C., Stellato C., Beck L.A. Chemokines: key players in innate and adaptive immunity. J Invest Dermatol 2005, 125:615-628.
17. Kaneko H., Ogasawara H., Naito T., Akimoto H., Lee S., Hishikawa T., et al. Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol 1999, 26:568-573.
18. Barbado J., Vega L., Gonzalez-Gallego R., Jimeno A., Ortiz De Lejarazu R., et al. MCP-1 in urine as biomarker of renal lupus in absence of cytokines, interferon-gamma and growth factors. Reumatol Clin 2010, 6:296-298.
19. Kiani A.N., Johnson K., Chen C., Diehl E., Hu H., Vasudevan G., et al. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 2009, 36:2224-2230.
20. Marks S.D., Williams S.J., Tullus K., Sebire N.J. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant 2008, 23:3521-3526.
21. Wagrowska-Danilewicz M., Stasikowska O., Danilewicz M. Correlative insights into immunoexpression of monocyte chemoattractant protein-1, transforming growth factor beta-1 and CD68+ cells in lupus nephritis. Pol J Pathol 2005, 56:115-120.